Skip to main content
Clinical Trials/CTRI/2014/09/005070
CTRI/2014/09/005070
Completed
未知

Intravitreal Bevacizumab Versus Triamcinolone for Treatment of Diabetic Macular Edema-- One Year Results

ethradhama Superspeciality Eye Hospita0 sites15 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- DIABETES MELLITUS
Sponsor
ethradhama Superspeciality Eye Hospita
Enrollment
15
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ethradhama Superspeciality Eye Hospita

Eligibility Criteria

Inclusion Criteria

  • All Patients with clinically significant macular oedema (according to ETDRS study) with systemic diabetis mellitus of \> 3 months duration.
  • Patients were required to have a baseline CRT of at least 300 um and BCVA of 20/25 to 20/400 Snellen equivalent in the study eye.
  • Patients with HbA1c controlled at less than 8\.0% at the beginning and during the study duration.

Exclusion Criteria

  • Patients with bilateral macular oedema, with retinal thickness difference between two eyes of \>100um.
  • Patient with history of
  • Macular Laser Photocoagulation
  • Intravitreal Injection Therapy
  • Active Proliferative Diabetic Retinopathy (PDRP) With Necessity Of Panretinal Laser Treatment
  • Panretinal Laser Treatment Within The Past 3 Months
  • Previous vitreous surgery
  • IHD \& CVA

Outcomes

Primary Outcomes

Not specified

Similar Trials